Skip to main content
Premium Trial:

Request an Annual Quote

Traversa Inks Deal to Evaluate siRNA Delivery Technology with Sanofi-Aventis

Premium

Traversa Therapeutics announced this week that it has signed a research agreement with Sanofi-Aventis for the development of the RNAi shop's delivery technology.

The technology, dubbed PTD-DRBD, comprises protein transduction domains linked with a double-stranded RNA binding domain.

According to Traversa, an siRNA coated with PTD-DRBD molecules binds to cell-surface proteoglycans, which stimulates macropinocytosis. The drug then enters the cell inside a macropinosome, at which point the pH inside the vesicle drops and the siRNA is released from the PTD-DRBD molecules into the cytoplasm.

Under the agreement, the companies will examine the ability of the PTD-DRBD technology to deliver siRNAs against undisclosed targets, with an eye toward developing RNAi therapeutics. Additional terms were not disclosed.

“This agreement will allow Sanofi-Aventis to select lead RNAi candidates and provide Traversa with a better understanding of the strengths of our RNAi delivery technology," Traversa President and CEO Hans Petersen said in a statement. "We are excited to be working with Sanofi-Aventis to conduct this research, and hope to advance the treatments selected during this collaboration into [investigational new drug application]-enabling studies and into the clinic.”

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.